Pharmacological inhibition of PAK6 perturbs the RAS/MAPK pathway and mitochondrial activity, sensitising therapy‐resistant leukaemic stem cells in chronic myeloid leukaemia to tyrosine kinase inhibitors.56 Here, PAK6 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.